Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
121.50    -0.50 (-0.41%)
Bid:
120.00
Ask:
122.00
Spread: 2.00 (1.667%)
Market Cap: £95.35m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Trading Update

12 Jan 2023 07:00

RNS Number : 4516M
Xaar PLC
12 January 2023
 

 

 

XAAR plc 

 

TRADING UPDATE

 

Xaar plc ("Xaar", "the Group" or "the Company"), the leading inkjet printing technology group, today announces a trading update for the year ended 31 December 2022.

 

TRADING

Strong revenue growth and full-year profitability

· Revenue for the period is expected to be approximately £74 million (2021: £59.3 million), representing year on year growth of 24% driven by a combination of organic growth (9%) and acquisitions

 

· The Group is expected to deliver an on track adjusted profit for the year

 

· During 2022 the Group continued to invest in working capital and infrastructure development and in March completed the acquisition of Megnajet

 

 

Further operational and strategic progress

· Further progress was made throughout the year in implementing the strategy to achieve long-term profitable growth

 

· Successful launch of Aqueous printhead product in November 2022 as planned, and on budget, is receiving strong customer engagement

 

· Factory reorganisation commenced in December and is progressing well and on schedule for completion by March 2023. This project is expected to deliver increased efficiency, reduce power usage, and reduce costs

 

· The integration of recent acquisitions (FFEI and Megnajet) has been completed successfully and both are contributing positively to Group results 

 

· Continued progress at EPS delivered its best performance to date with revenue growth of 36%

 

 

Challenging macro conditions expected to continue into 2023

· Sales volumes in the Printhead business continue to be affected by the uncertainty in China, which is expected to continue in the short term as Covid cases increase. At this stage it remains unclear when normal levels of business will return

 

· We have maintained our policy of increased investment in inventory to ensure availability of product during the factory reorganisation in Q1 2023 and the remainder of the year

 

BALANCE SHEET AND LIQUIDITY

· The Group remains well capitalised with a strong balance sheet with a net cash position as at 31 December 2022 of £8.6 million

 

 

John Mills, Chief Executive Officer, commented:

"I am hugely proud of the team in delivering a strong performance and making further progress with our strategy. We expect to deliver strong profitable revenue growth and the important milestone of achieving full year profitability representing great progress against our plan and remain well positioned for the business to achieve its exciting potential.

Aquinox has been successfully launched and is already being well received by our customers. With the operational improvements now well underway, notwithstanding the challenging external environment, the business is in good shape to continue to make further progress over the long term."

 

 

 

 

 

 

 

 

 

 

Enquiries:

 

Xaar plc

+44 (0) 1223 423 663 

Ian Tichias, Chief Financial Officer

John Mills, Chief Executive Officer

 

Tulchan Communications

Giles Kernick

Olivia Lucas

+44 (0) 207 353 4200

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSFIFWFEDSEDF
Date   Source Headline
3rd Feb 20254:15 pmRNSTotal Voting Rights
22nd Jan 202512:30 pmRNSBlock listing Interim Review
21st Jan 20253:00 pmRNSHolding(s) in Company
15th Jan 20257:00 amRNSTrading update & notification of full year results
15th Jan 20257:00 amRNSAppointment of Chief Financial Officer
11th Dec 202410:30 amRNS2024 Full Year Trading Update
4th Dec 202410:45 amRNSUpdate statement on 2024 AGM voting results
3rd Dec 202410:50 amRNSTotal Voting Rights
20th Nov 20247:00 amRNSBoard changes
1st Nov 202412:00 pmRNSTotal Voting Rights
1st Oct 202411:30 amRNSTotal Voting Rights
18th Sep 20247:00 amRNSInterim Results
2nd Sep 20241:45 pmRNSTotal Voting Rights
2nd Aug 20242:30 pmRNSHolding(s) in Company
1st Aug 202411:15 amRNSTotal Voting Rights
30th Jul 20247:00 amRNSNOTICE OF RESULTS AND UPDATE ON TRADING
3rd Jul 202411:45 amRNSBlock listing Interim Review
2nd Jul 20242:00 pmRNSTotal Voting Rights
28th Jun 202410:00 amRNSDirector Declaration
3rd Jun 20242:45 pmRNSTotal Voting Rights
30th May 202412:00 pmRNSBoard changes
29th May 20241:45 pmRNSResult of AGM
29th May 20249:30 amRNSHolding(s) in Company
21st May 20249:30 amRNSDirector/PDMR Shareholding
20th May 20244:30 pmRNSDirector/PDMR Shareholding
13th May 20249:42 amRNSHolding(s) in Company
1st May 20244:15 pmRNSTotal Voting Rights
30th Apr 20244:30 pmRNSDirector/PDMR Shareholding
22nd Apr 202410:51 amRNSAnnual Financial Report
2nd Apr 202412:00 pmRNSTotal Voting Rights
1st Mar 202410:15 amRNSTotal Voting Rights
26th Feb 20249:00 amRNSHolding(s) in Company
23rd Feb 202410:30 amRNSBoard Change
1st Feb 20241:32 pmRNSTotal Voting Rights
29th Jan 202412:04 pmRNSHolding(s) in Company
12th Jan 20243:15 pmRNSBlock listing Interim Review
12th Jan 20247:00 amRNSNotification of Results & Full year Guidance
8th Jan 202412:36 pmRNSTotal Voting Rights
12th Dec 20239:00 amRNSNotification of Transactions of Directors & PDMRs
11th Dec 20233:00 pmRNSNotification of Transactions of Directors & PDMRs
1st Dec 202311:00 amRNSTotal Voting Rights
1st Dec 202310:00 amRNSDirector Declaration
29th Nov 20237:00 amRNSTrading Update
17th Nov 20234:07 pmRNSHolding(s) in Company
9th Nov 20231:53 pmRNSDirector/PDMR Shareholding
3rd Nov 202310:52 amRNSHolding(s) in Company
1st Nov 20234:03 pmRNSTotal Voting Rights
30th Oct 20237:00 amRNSBoard Changes
2nd Oct 202311:45 amRNSTotal Voting Rights
21st Sep 20233:16 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.